Sinopharm unit, CanSinoBIO apply in China for COVID-19 vaccines' public use approval
(Reuters) – A unit of China National Pharmaceutical Group (Sinopharm) and CanSino Biologics Inc (CanSinoBIO) have applied for public use
Read more
(Reuters) – A unit of China National Pharmaceutical Group (Sinopharm) and CanSino Biologics Inc (CanSinoBIO) have applied for public use
Read more